Minerva Neurosciences, Inc. (NERV)
NASDAQ: NERV · Real-Time Price · USD
6.60
+0.37 (5.94%)
At close: Feb 27, 2026, 4:00 PM EST
6.47
-0.13 (-1.97%)
After-hours: Feb 27, 2026, 6:22 PM EST
Minerva Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
285.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 41.18M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| X4 Pharmaceuticals | 33.98M |
| C4 Therapeutics | 30.11M |
| Silence Therapeutics | 25.83M |
| OmniAb | 21.09M |
| Alector | 21.05M |
| Shattuck Labs | 1.00M |
| Abeona Therapeutics | 400.00K |
| Inhibikase Therapeutics | 1.00 |
NERV News
- 25 days ago - Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript - Seeking Alpha
- 4 weeks ago - Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026 - GlobeNewsWire
- 3 months ago - Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors - GlobeNewsWire
- 4 months ago - Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 4 months ago - Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved - GlobeNewsWire
- 7 months ago - Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results - GlobeNewsWire
- 10 months ago - Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 1 year ago - Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates - GlobeNewsWire